Clinical Trials Logo
  1. Home
  2. Carcinoma Breast Stage IV
  3. NCT02183805

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

Carcinoma Breast Stage IV Clinical Trial

Official title:
Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer

Clinical Trial Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

Clinical Trial Description

To explore the progression-free survival of patients with metastatic triple-negative breast cancer treated with peripheral blood stem cell transplant (PBSCT) followed by high dose chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02183805
Study type Interventional
Source Sun Yat-sen University
Contact
Status Terminated
Phase Phase 2
Start date June 17, 2014
Completion date December 15, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03511781 - Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer N/A
Completed NCT00199212 - PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 Phase 1
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Active, not recruiting NCT02755272 - A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Phase 2
Withdrawn NCT02140437 - Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Phase 2
Terminated NCT01531764 - BIBW 2992 (Afatinib) and Vinorelbine Phase 2
Completed NCT00669565 - Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Withdrawn NCT01906112 - Role of Surgery for the Primary in Patients With Breast Cancer Stage IV. Phase 3
Recruiting NCT02161315 - Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer N/A
Completed NCT00433095 - Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer Phase 2